Search clinical trials for: Fluarix-AS01E

Total 251 results

GlaxoSmithKline

Completed

Safety Study of Four Candidate Influenza Vaccines to Prevent Influenza Disease in the Elderly Population

Influenza

Belgium
University of Oxford

Completed

Malaria Vaccine Safety and Immunogenicity Study in Healthy Adults (RTSS)

Malaria Vaccine

Thailand
GlaxoSmithKline
The PATH Malaria Vaccine Initiative (MVI)

Completed

Efficacy, Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine Evaluating Different Dose Schedules in a Sporozoite Challenge Model in Healthy Malaria-naïve Adults

Malaria

United States
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine With Various Formulations in Adults >= 50 Years

Herpes Zoster

United States, Spain, Czechia
GlaxoSmithKline

Completed

A Study to Assess the Safety, Reactogenicity and Immune Response of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3844766A) in Older Adults

Respiratory Syncytial Virus Infections

United States, Belgium
University of Oxford
National Institute for Health Research, United Kingdom; The PATH Malaria Vaccine...

Completed

A Safety and Efficacy Study of Concomitant Administration of ChAd63/MVA ME-TRAP + RTS,S

Plasmodium Falciparum Malaria

United Kingdom
GlaxoSmithKline

Completed

Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine (SB257049) Evaluating Schedules With or Without Fractional Doses, Early Dose 4 and Yearly Doses, in Children 5-17 Months of Age

Malaria

Ghana, Kenya
GlaxoSmithKline

Completed

A Study to Evaluate the Reactogenicity, Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Investigational Supra-seasonal Universal Influenza Vaccines - Inactivated (SUIVs) (GSK3816302A) in Healthy Adults Aged 18 to 39 Years

Influenza, Human

United States, Belgium
GlaxoSmithKline

Completed

Safety Study of an Adjuvanted Candidate Influenza Vaccine to Prevent Influenza Disease in the Elderly Population

Influenza

Belgium
GlaxoSmithKline
PATH

Completed

A Study to Evaluate the Efficacy, Immunogenicity and Safety in a Sporozoite Challenge Model of a Fractional Booster Dose of GSK Biologicals' Candidate Malaria Vaccine Administered to Previously Vaccinated Healthy Malaria-naïve Adults

Malaria

United States
GlaxoSmithKline

Completed

A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GlaxoSmithkline (GSK) Biologicals' Investigational Vaccine GSK2838504A When Administered to Chronic Obstructive Pulmonary Disease (COPD) Patients With Persistent Airflow Obstruction.

Respiratory Disorders

Sweden, United Kingdom
University of Oxford
National Institute for Health Research, United Kingdom; The PATH Malaria Vaccine...

Completed

A Phase I/IIa Study of the Safety, Immunogenicity and Efficacy of FMP2.1/AS01B, an Asexual Blood-Stage Vaccine for Plasmodium Falciparum Malaria

Plasmodium Falciparum Malaria

United Kingdom
Sun Pharmaceutical Industries Limited

Completed

Efficacy and Safety of AS012 in Subjects With Non-segmental Vitiligo

Non-segmental Vitiligo

United States, India
GlaxoSmithKline

Completed

A Study for Evaluation of Immunogenicity and Reactogenicity of Fluarix™ / Influsplit SSW® 2008/2009 in Adults

Influenza

Germany
Bill & Melinda Gates Medical Research Institute
Bill and Melinda Gates Foundation; Wellcome Trust

Recruiting

Study to Assess Efficacy and Safety of M72/AS01E-4 Mycobacterium Tuberculosis (Mtb) Vaccine in Adolescents and Adults

Tuberculosis

Indonesia, Kenya, South Africa, Vietnam, Malawi, Mozambique, Zambia
GlaxoSmithKline

Completed

A Study for Evaluation of Immunogenicity and Reactogenicity of FluarixTM / Influsplit SSW® 2009/2010 in Adults

Influenza

Germany
Public Health England
Royal Free and University College Medical School

Completed

Response of Older Adults to Influenza Vaccination With Regard to Cytomegalovirus (CMV) Status (CMVflu)

Influenza

United Kingdom
GlaxoSmithKline

Completed

Incidence of Influenza, Downstream Complications of Influenza & Hospitalizations in Elderly Vaccinated With Fluarix™

Influenza

Australia, Brazil
GlaxoSmithKline

Completed

Study to Evaluate the Safety and Immunogenicity of Fluarix™ 2006/2007 in Adults Aged 18 Years or Above

Influenza

Germany
National Institute of Allergy and Infectious Diseases...

Completed

Fluarix Immunogenicity and Safety Trial

Influenza

United States
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccine When Administered in Children Who Previously Participated in Study 115345

Influenza

Spain, Czechia, United Kingdom, Poland
GlaxoSmithKline

Completed

A Study to Demonstrate the Efficacy of GSK Biologicals' Influenza Vaccine in Adults

Influenza

Finland, Czech Republic
Emory University

Terminated

The Impact of Imprinting and Repeated Influenza Vaccination on Adaptive Immunity, Transcriptomics, and Metabolomics (FLU2)

Influenza

United States
GlaxoSmithKline

Completed

Study on the Incidence of Influenza and Its Complications, in Subjects Aged 50 Years and Over Vaccinated With Fluarix™

Influenza

United States, Germany, Poland, Netherlands
GlaxoSmithKline

Completed

Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine Versus a Licensed Comparator in Children

Influenza

United States, Taiwan, Thailand, Hong Kong, Mexico
Bill & Melinda Gates Medical Research Institute
Wellcome Trust

Completed

Safety and Immunogenicity of a Mycobacterium Tuberculosis Vaccine M72/AS01E in Participants With Well-controlled HIV (MESA-TB)

Human Immunodeficiency Virus

South Africa
PATH
GlaxoSmithKline; Kenya Medical Research Institute; US Army Medical Research Directorate-Africa... and other collaborators

Completed

RTS,S/AS01E Hypo-immuno-responsiveness Study

Plasmodium Falciparum

Kenya
GlaxoSmithKline

Completed

A Study to Assess the Safety and Immune Response of Quadrivalent Seasonal Influenza Vaccine (Fluarix Tetra) in Participants Aged 65 Years and Older in India

Influenza, Human

India
GlaxoSmithKline

Completed

Study to Evaluate the Immunogenicity and Safety of 2 Formulations of GlaxoSmithKline (GSK) Biologicals' GSK1247446A Low Dose Influenza Vaccine Candidate

Influenza

Belgium
GlaxoSmithKline

Completed

Study Comparing the Immune Response and Safety of Fluarix and Fluzone Influenza Vaccines in Children

Influenza

United States
Institut Paoli-Calmettes

Completed

Phase I/II Study of Immune Therapy After Allograft in Patients With Myeloid Hemopathy (ALLO-WT1)

Acute Myeloid Leukemia | Chronic Myeloid Leukemia | Myelodysplastic Syndrome

France
Northwestern University

Completed

Influenza Vaccine Responses as a Means of Assessing Immune Competence in Chimeric Kidney/Stem Cell Transplant Recipients

Influenza

United States
NanoPass Technologies Ltd

Completed

A Pilot Study to Evaluate the Safety and Immunogenicity of Low Dose Flu Vaccines (NANOVAX)

Influenza, Human
GlaxoSmithKline

Completed

Immunogenicity, Safety of GSKs Tdap Vaccine Boostrix When Coadministered With GSKs Influenza Vaccine Fluarix in Adults

Tetanus | Diphtheria | Acellular Pertussis

United States
Vanderbilt University Medical Center
Duke University; Centers for Disease Control and Prevention; Children's Hospital...

Completed

Influenza Vaccine Feasibility Study in Children With Persistent Asthma

Asthmatic

United States
GlaxoSmithKline

Completed

Demonstrate the Superiority of the Immune Response of Adjuvanted Influenza Vaccine Induced in an Adult Population

Influenza

Germany, United States, Belgium, Norway
GlaxoSmithKline

Completed

Study to Evaluate Reactogenicity and Immunogenicity of Revaccination With Adjuvanted Influenza Vaccine in Elderly Adults

Influenza

Belgium
University of Surrey

Completed

T-cell Diversity Following Intranasal and Intramuscular Vaccines

Influenza

United Kingdom
National Institute of Allergy and Infectious Diseases...

Completed

Influenza Vaccine in Pregnant Women

Influenza

United States
GlaxoSmithKline

Completed

A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Seasonal Influenza Vaccine in Children

Influenza

Spain, Taiwan, Canada, United States, Mexico
Medigen Vaccine Biologics Corp.

Completed

A Study to Evaluate the Safety and Immunogenicity of Quadrivalent Influenza Vaccine

Influenza

Taiwan
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of Fluarix™ Vaccine in Children Who Have Previously Been Vaccinated With Pandemrix™

Influenza

Sweden, Netherlands
GlaxoSmithKline

Completed

A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Seasonal Influenza Vaccine in Adults

Influenza

Germany
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of a GlaxoSmithKline Biologicals' Candidate Influenza Vaccine in Healthy Children

Influenza

Mexico
GlaxoSmithKline

Completed

A Study for Evaluation of Immunogenicity and Reactogenicity of Fluarix/Influsplit SSW 2012/2013 in People Aged 18 Years and Above

Influenza

Germany
GlaxoSmithKline

Completed

Study to Evaluate Reactogenicity and Immunogenicity of Revaccination With Adjuvanted Influenza Vaccine in Elderly

Influenza

Belgium
U.S. Army Medical Research and Development Command
GlaxoSmithKline; United States Agency for International Development (USAID); The...

Completed

A Study to Determine Whether 2 Investigational Malaria Vaccines Are Safe, Protective Against Malaria in Adults

Malaria

United States
U.S. Army Medical Research and Development Command
GlaxoSmithKline; United States Agency for International Development (USAID); Walter... and other collaborators

Completed

Phase 1 Clinical Trial With Controlled Human Malaria Infection (CHMI) to Evaluate the Safety and Efficacy of the Plasmodium Falciparum Vaccine Candidate FMP012 Administered Intramuscularly With AS01B Adjuvant System in Healthy Malaria-Naïve Adults

Malaria

United States
GlaxoSmithKline

Completed

Study to Evaluate Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine GSK2282512A When Administered to Children 6 to 35 Months of Age

Influenza

Canada, Honduras, Dominican Republic
GlaxoSmithKline

Completed

Revaccination With Influenza Vaccine GSK1247446A

Influenza | Influenza, Human

Belgium

3

Subscribe